Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and Bortezomib in Relapsed/Refractory AIHA
NCT04083014Phase 2Completed
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2019
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies, Modified Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, bortezomib in warm autoimmune hemolytic anemia (wAIHA), Evans syndrome, sponsored by Peking Union Medical College Hospital. Started Aug 2019; status: completed.
02
Drugs
rituximabbortezomib
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)Evans syndrome
Beyond the preview
Go deeper on NCT04083014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04083014.